Search clinical trials for: KN035

Total 27 results

Nanjing First Hospital, Nanjing Medical University

Recruiting

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Gastrointestinal Neoplasms

China
池畔

Not yet recruiting

Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer (TRACE-LE)

Rectal Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
The First Affiliated Hospital of Soochow University
MITRO Biotech Co., Ltd.

Unknown

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

KN035 for dMMR/MSI-H Advanced Solid Tumors

Solid Tumor

China
RenJi Hospital

Unknown

KN035 in Patients With Advanced Multiple Primary Tumors (CPOG035-01)

Multiple Primary Neoplasm

China
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
Northern Jiangsu Province People's Hospital

Recruiting

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

NSCLC

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Thymic Carcinoma

China
Peking University Third Hospital

Not yet recruiting

Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Cervical Cancer
Tracon Pharmaceuticals Inc.

Recruiting

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)

Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma

United States, United Kingdom
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Unknown

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

HER2-positive Breast Cancer
Sun Yat-sen University

Not yet recruiting

A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Potentially Resectable Hepatocellular Carcinoma
Chongqing University Cancer Hospital

Not yet recruiting

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Tracon Pharmaceuticals Inc.

Active, not recruiting

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Soft Tissue Sarcoma | Advanced Sarcoma | Metastatic Sarcoma

United States
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Terminated

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase I Trial of Envafolimab for Healthy Male Subjects

Healthy Male

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China

3

Subscribe